Orthocell Ltd ( (AU:OCC) ) has issued an update.
Orthocell Limited announced a webinar presentation by CEO Paul Anderson to discuss the global expansion of their product Remplir™, which has recently received approval in Australia, New Zealand, and Singapore. This expansion is part of Orthocell’s strategy to enhance its market positioning and accelerate the development of its tendon cell therapy in the US, aiming to engage with the FDA and prepare for partnering discussions.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company based in Perth, Australia, focusing on developing products for the repair of bone and soft tissue injuries. Their product portfolio includes the CelGro™ platform of collagen medical devices for tissue reconstruction, Striate+™ for dental GBR applications, and Remplir™ for peripheral nerve reconstruction. The company is also working on SmrtGraft™ for tendon repair and autologous cell therapies for tendon and cartilage regeneration, with a focus on accelerating tendon cell therapy development in the US.
YTD Price Performance: -3.31%
Average Trading Volume: 1,874,100
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$317.2M
Learn more about OCC stock on TipRanks’ Stock Analysis page.